TPCA-1: Selective IKK-2 Inhibitor for NF-κB Pathway Research

Executive Summary: TPCA-1 (2-(carbamoylamino)-5-(4-fluorophenyl)thiophene-3-carboxamide, SKU A4602) is a potent, selective small molecule inhibitor of human IκB kinase 2 (IKK-2), exhibiting 550-fold selectivity over ten other kinases including COX-1 and COX-2 (APExBIO). It blocks the NF-κB pathway by targeting IKK-2, suppressing LPS-induced TNF-α, IL-6, and IL-8 production in human monocytes with IC50 values of 170–320 nM (Du et al., 2021). In vivo, TPCA-1 reduces arthritis severity in murine collagen-induced arthritis models at 3–20 mg/kg doses. The compound is insoluble in water but dissolves readily in DMSO and ethanol. TPCA-1 is for research use only and is distributed by APExBIO.

Biological Rationale

NF-κB is a central transcription factor regulating inflammatory gene expression. IκB kinase 2 (IKK-2/IKKβ) phosphorylates IκBα, leading to its degradation and subsequent NF-κB nuclear translocation. Dysregulation of this pathway is implicated in autoimmune diseases, chronic inflammation, and cancer (Du et al., 2021). Selective inhibition of IKK-2 enables targeted suppression of proinflammatory cytokine production, providing mechanistic insights and potential therapeutic leads. TPCA-1’s selectivity allows for precise dissection of IKK-2-dependent signaling without significant off-target kinase inhibition (APExBIO).

Mechanism of Action of TPCA-1

TPCA-1 is a small molecule that selectively inhibits the catalytic activity of IKK-2. By binding to the ATP-binding site, TPCA-1 prevents phosphorylation of IκBα. This blocks degradation of IκBα, retaining NF-κB dimers in the cytoplasm and inhibiting their nuclear localization. Consequently, transcription of proinflammatory genes such as TNF-α, IL-6, and IL-8 is suppressed. TPCA-1’s high selectivity for IKK-2 (over IKK-1 and other kinases) enables isolation of IKK-2-specific signaling effects (APExBIO).

Evidence & Benchmarks

• TPCA-1 inhibits LPS-induced TNF-α, IL-6, and IL-8 production in human monocytes with IC50 values of 170–320 nM (in vitro, 37°C, serum-supplemented RPMI) (APExBIO).
• Demonstrates ~550-fold selectivity for IKK-2 over other kinases, including COX-1 and COX-2 (enzyme panel, see Table 1 in product data).
• In DBA/1 mice, prophylactic administration at 3, 10, or 20 mg/kg i.p. twice daily significantly reduces collagen-induced arthritis severity; effect is comparable to etanercept (control, n≥8 per group, see in vivo data, APExBIO).
• Reduces paw tissue levels of IL-1β, IL-6, TNF-α, and IFN-γ in murine models (ELISA quantification, 24-hour endpoint) (Du et al., 2021).
• TPCA-1 does not inhibit IKK-1 or upstream kinases TAK1, c-Src, or downstream COX-1/2 at relevant concentrations (APExBIO).

This article further details mechanism and protocol clarity compared to 'TPCA-1 (SKU A4602): Reliable IKK-2 Inhibition for Reprodu...', which focuses primarily on troubleshooting cell-based assays. Here, we provide updated benchmarks and direct mechanistic links to NF-κB and apoptosis/necroptosis research.

For a scenario-driven discussion of TPCA-1’s use in cell viability and cytokine inhibition, see 'TPCA-1 (A4602): Reliable IKK-2 Inhibition in Cell-Based A...'. Our article extends these findings by including recent in vivo and molecular selectivity results.

Applications, Limits & Misconceptions

TPCA-1 has become a reference IKK-2 inhibitor in NF-κB pathway, cytokine release, and autoimmune disease models. Its use spans:

• Dissecting IKK-2-dependent NF-κB signaling in immune and cancer cells.
• Suppressing LPS- or TNF-α-induced proinflammatory cytokine production.
• Modeling rheumatoid arthritis and other inflammation-driven diseases in mice.
• Comparative efficacy studies versus biologic agents (e.g., etanercept).

Common Pitfalls or Misconceptions

• TPCA-1 is not a pan-IKK inhibitor: It is highly selective for IKK-2; IKK-1 and upstream kinases are not significantly inhibited at working concentrations (APExBIO).
• Not suitable for clinical or diagnostic use: TPCA-1 is for research use only and has not been approved for human or veterinary therapy.
• Low aqueous solubility: TPCA-1 is insoluble in water; use DMSO (≥13.95 mg/mL) or ethanol (≥2.53 mg/mL with warming/ultrasonication) for stock preparation.
• Long-term solution storage is discouraged: Prepare fresh working solutions or store aliquots at -20°C; avoid repeated freeze-thaw cycles.
• Does not block all NF-κB activation: Non-canonical NF-κB pathways and IKK-1-dependent responses may remain active.

For an in-depth perspective on TPCA-1’s impact on regulated cell death, see 'TPCA-1: Illuminating IKK-2 Inhibition in Advanced Cell De...', which this article updates with direct benchmarks and solubility parameters.

Workflow Integration & Parameters

• Stock Preparation: Dissolve TPCA-1 powder in DMSO to ≥13.95 mg/mL or in ethanol to ≥2.53 mg/mL (with warming and ultrasonication).
• Storage: Store desiccated powder at -20°C. Stock solutions may be stored at -20°C for several months; avoid long-term storage of dilute solutions.
• Working Concentrations: For cell-based assays, 0.1–10 μM is typical; always optimize for cell type and endpoint.
• Controls: Include vehicle (DMSO/ethanol) and positive controls (e.g., etanercept in arthritis models).
• Species/Cross-reactivity: Validated in human and murine systems; check literature for other species.

Conclusion & Outlook

TPCA-1 (A4602, APExBIO) remains a benchmark tool for selective inhibition of IKK-2 and NF-κB pathway studies. Its high selectivity, potency, and defined solubility/storage parameters support reproducible research in immunology and inflammation. Future work may use TPCA-1 to dissect pathway crosstalk in regulated cell death and chronic disease (Du et al., 2021).

For detailed product specifications, protocols, and ordering information, visit the TPCA-1 product page.